The finding of increased abundance of USP48 protein, which was explored given the potential mechanistic link between MDM2 inhibition efficacy in GATA3mut breast cancer, supported the hypothesis that GATA3 mutations were leading to changes in the MDM2 signaling pathway, which in turn lead to the therapeutic vulnerability of MDM2 inhibition. This evidence concerns the gene GATA3 and breast carcinoma.